|
|
 |
|
Viewing report
|
|
|
|
Special Report: Can Innovation Supplant Convention in Sarcoidosis Treatment?
Decision Resources, Inc., Sep 2009, Pages: 24
“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline. However, opportunity remains for an agent that can address some of the unmet needs in this market.
Questions Answered in This Report
Sarcoidosis is an inflammatory disease that is hallmarked by the development of granulomas.
- What organ systems are affected by sarcoidosis?
- How is the disease diagnosed?
- What is the prognosis for patients with sarcoidosis?
Sarcoidosis affects only a small percentage of the population.
- How many people were hospitalized with sarcoidosis in 2008?
- Is this population expected to grow?
Patients with chronic sarcoidosis will require multiple treatment courses throughout their lifetime.
- What are the current treatments for sarcoidosis?
- What are their benefits and drawbacks?
- How do emerging treatments compare with current offerings?
Reimbursement challenges loom large in this market.
- What effect are they having on sales?
- How might companies overcome these challenges?
- What are the ideal characteristics of an agent positioned to capture the sarcoidosis market?
Scope
- Overview of sarcoidosis: Pathophysiology and etiology, symptoms, diagnosis.
- Epidemiology: Decision Resources epidemiology analysis of the diagnosed incidence and the number of patients hospitalized with sarcoidosis in the United States, 2008-2018.
- Current treatments: Corticosteroids, methotrexate, antimalarials, TNF-a inhibitors.
- Emerging treatments: Celgene’s apremilast, MondoBiotech/Biogen Idec’s aviptadil, Centocor/Medarex’s Stelara, ongoing academic research.
- Market: 2008 sales, opportunities and challenges for emerging agents, remaining unmet need, outlook for the sarcoidosis market.
- Primary research: Interviews with thought leaders in sarcoidosis.
Customers who bought this item also bought
Sarcoidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Special Report: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis
Chronic Lymphocytic Leukemia: Off-Label Prescribing Drives Market Growth
Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease
Ankylosing Spondylitis: Surveyed Rheumatologists Await Non-TNF-Alpha Inhibitor Therapies in an Underserved Market
Autoimmune Disease Series: Strategies for Success in the Challenging Sjögren's Syndrome Market
Juvenile Idiopathic Arthritis - Disease-Subtype Heterogeneity Drives Diverse Treatment Options
Autoimmune Market Forecast to 2014
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
The Immunomodulators Market Outlook to 2016
|
|
|
|
